With An Additional Active Ingredient (excludes Reaction Product Or Complex) Patents (Class 514/154)
-
Publication number: 20080260796Abstract: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.Type: ApplicationFiled: April 17, 2008Publication date: October 23, 2008Applicant: MEDTRONIC, INC.Inventors: Thomas C. Bischoff, William V. Ferris
-
Patent number: 7435380Abstract: A pseudo-plastic or thixotropic carrier having anti-malodorous components dissolved or suspended therein is sprayed on the internal surfaces of an ostomy bag or pouch. The viscoelastic properties of the carrier allow the composition to be conveniently dispensed from a spray bottle into the ostomy bag and retained on the inner walls thereof without being displaced therefrom by incoming waste during use of the ostomy bag. This allows the composition to continue to deodorize the ostomy bag headspace even after waste material begins to fill the bag.Type: GrantFiled: September 30, 2002Date of Patent: October 14, 2008Assignee: Church & Dwight Co., Inc.Inventor: Anthony E. Winston
-
Publication number: 20080233206Abstract: The present invention relates to an improved method for treating a wide range of inflammatory disorders by administering a tetracycline compound together with an effective inhibitor of tetracycline absorption, such as polyvalent metals. Pharmaceutical compositions used in that method are also taught.Type: ApplicationFiled: March 21, 2008Publication date: September 25, 2008Applicant: Molecular Research Center, Inc.Inventor: Piotr Chomczynski
-
Patent number: 7425573Abstract: Treating or preventing degeneration or destruction of articular cartilage and/or subchondral bone in the affected joint of a mammal is accomplished by administering a compound of formula (I), wherein the variables have the meanings given in the present description. A preferred compound of formula (I) is formula (II).Type: GrantFiled: August 29, 2002Date of Patent: September 16, 2008Assignees: Merckle GmbH, Ascentia Pharma Inc.Inventors: Jean-Pierre Pelletier, Johanne Martel-Pelletier
-
Publication number: 20080206293Abstract: This invention relates to antimicrobial wound dressings having a non-leaching antimicrobial activity, releasable antimicrobial and antiprotease agents, and a controlled-release bioactive agent such as doxycycline. The Wound dressing material is absorbent and acts as a substrate for antimicrobial and antiprotease agents as well as bioactive agents. More generally, this invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings, powders and other substrates. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymeric molecules and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial efficacy.Type: ApplicationFiled: February 22, 2008Publication date: August 28, 2008Applicants: QUICK-MED TECHNOLOGIES, INC., UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: William Toreki, Bernd Liesenfeld, David Moore, Gregory Schultz, Gerald Olderman, Gregory Staab
-
Patent number: 7414041Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.Type: GrantFiled: February 2, 2004Date of Patent: August 19, 2008Assignee: Trustees Of Tufts CollegeInventor: Stuart B. Levy
-
Publication number: 20080188446Abstract: Pharmaceutical formulations containing tetracycline for topical administration, as well as methods of making and administering the same, are disclosed.Type: ApplicationFiled: February 1, 2008Publication date: August 7, 2008Applicant: WARNER CHILCOTT COMPANY INC.Inventors: Brendan Muldoon, David Woolfson, Stephen McCullagh
-
Publication number: 20080161273Abstract: The present invention provides a method of administering adapalene for the maintenance therapy of acne vulgaris to prevent acne recurrence or reduce the severity of the acne recurrence.Type: ApplicationFiled: October 20, 2005Publication date: July 3, 2008Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Stephanie Arsonnaud, Pascale Soto
-
Publication number: 20080145336Abstract: Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.Type: ApplicationFiled: February 15, 2008Publication date: June 19, 2008Inventors: George W. Muller, Hon-Wah Man
-
Publication number: 20080118436Abstract: An object of the present invention is to provide a pathologic model animal more accurately reflecting the pathologic conditions of nonalcoholic steatohepatitis patients, and the present invention provides the pathologic model animal for nonalcoholic steatohepatitis produced by continuously administering a tetracycline antibiotic to an animal having its body weight significantly increased compared with that of a group fed with a normal diet by feeding it with a high-fat diet.Type: ApplicationFiled: September 13, 2005Publication date: May 22, 2008Inventors: Jun Suzuki, Hisashi Iwaasa, Minoru Sasaki, Makoto Ito, Akio Kanatani
-
Patent number: 7345024Abstract: The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs.Type: GrantFiled: June 20, 2003Date of Patent: March 18, 2008Assignee: Heraeus Kulzer GmbH & Co. KGInventors: Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kühn
-
Publication number: 20070212358Abstract: A composition comprises plasmin or an enzymatically equivalent derivative thereof and an inhibitor of at least an enzyme that is activatable, directly or indirectly, by plasmin or one of its enzymatically equivalent derivatives. The composition can be used to effect or induce a controlled posterior vitreous detachment (“PVD”) to prevent, treat, or ameliorate a potential complication of a pathological ocular condition. Such a composition can be administered intravitreally.Type: ApplicationFiled: February 23, 2007Publication date: September 13, 2007Inventor: Stephen P. Bartels
-
Patent number: 7253183Abstract: This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula -Alk1-C(?O)—R9, -Alk1-S(O)—R9 or -Alk1-S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl; R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, 4Type: GrantFiled: April 14, 2004Date of Patent: August 7, 2007Assignee: Janssen Pharmaceutica N.V.Inventors: David William End, Michael J. Zelesko
-
Patent number: 7238342Abstract: Methods and solutions are provided for removal of the smear layer on prepared tooth and bone surfaces, especially in endodontic environments.Type: GrantFiled: January 21, 2003Date of Patent: July 3, 2007Assignee: Dentsply InternationalInventors: Mahmoud Torabinejad, William B. Johnson
-
Patent number: 7112578Abstract: Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.Type: GrantFiled: January 12, 2004Date of Patent: September 26, 2006Inventor: Bruce Levin
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 7053073Abstract: A treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising a combination of valacyclovir hydrochloride, minocycline hydrochloride, and metronidazole.Type: GrantFiled: July 20, 2004Date of Patent: May 30, 2006Assignee: Ficaar, Inc.Inventors: Ernest L. Bonner, Jr., Robert Hines
-
Publication number: 20040235784Abstract: Disclosed are pharmaceutical preparations for use in the therapeutical and prophylactic treatment of bacterial and parasitic infections, especially malaria. The preparations contain as active substances 3-N-formyl-hydroxylaminopropyl phosphonic acid derivatives or 3-N-acetylhydroxylaminopropyl phosphonic acid derivatives and may be combined with other pharmaceutical active agents and/or other pharmaceutically acceptable excipients. Also disclosed are methods of treatments using such preparations.Type: ApplicationFiled: October 1, 2003Publication date: November 25, 2004Inventors: Hassan Jomaa, Jochen Wiesner
-
Patent number: 6765000Abstract: A treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising a combination of acyclovir, minocycline hydrochloride, and metronidazole. An alternate treatment comprises the combination of valacyclovir hydrochloride, minocycline hydrochloride, and metronidazole.Type: GrantFiled: October 15, 2002Date of Patent: July 20, 2004Inventors: Ernest L. Bonner, Jr., Robert Hines
-
Patent number: 6756365Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.Type: GrantFiled: February 16, 2000Date of Patent: June 29, 2004Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 6743805Abstract: This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula -Alk1-C(═O)—R9, -Alk1-S(O)—R9 or -Alk1-S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl; R6 and R7 each independently arType: GrantFiled: November 28, 2001Date of Patent: June 1, 2004Assignee: Janssen Pharmaceutica NVInventors: David William End, Michael J. Zelesko
-
Patent number: 6733764Abstract: The present invention comprises a method for the treatment of cancerous tumors in mammals comprising the administration of an effective amount of an immunostimulator which enhances and potentiates the mammals own immune system to selectively attack and kill the cancerous cells. The immunostimulator, preferably urushiol, is administered in a pharmaceutically acceptable carrier and can be co-administered in conjunction with other immunostimulators, radiation therapy or other cytotoxic anti-cancer agents to further enhance their effect.Type: GrantFiled: June 11, 2001Date of Patent: May 11, 2004Inventor: Alain Martin
-
Patent number: 6734194Abstract: This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(═O)—R9, —Alk1—S(O)—R9 or —Alk1—S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxy C1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6aType: GrantFiled: June 18, 2003Date of Patent: May 11, 2004Assignee: Janssen Pharmaceutica N.V.Inventors: David William End, Michael J. Zelesko
-
Patent number: 6677321Abstract: Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.Type: GrantFiled: November 28, 2000Date of Patent: January 13, 2004Inventor: Bruce Levin
-
Publication number: 20030181425Abstract: The present invention relates to pharmaceutical composition with lysergol as bioactive enhancer and bioavailability facilitator for broad-spectrum antibiotics. The present invention has direct implication in reducing the dosage of antibiotics while increasing the efficiency of absorption of nutritional elements.Type: ApplicationFiled: March 25, 2002Publication date: September 25, 2003Inventors: Suman Preet Singh Khanuja, Jai Shankar Arya, Santosh Kumar Srivastava, Ajit Kumar Shasany, Tiruppadiripuliyur Ranganathan Santha Kumar, Mahendra Pandurang Darokar, Sushil Kumar
-
Publication number: 20030181371Abstract: Compositions comprising collagen and at least one metalloprotease inhibitor, and methods of making and using same are provided.Type: ApplicationFiled: December 27, 2002Publication date: September 25, 2003Applicant: Angiotech Pharmaceuticals, Inc.Inventors: William L. Hunter, David M. Gravett, Philip M. Toleikis, Arpita Maiti
-
Publication number: 20030166585Abstract: Methods and compositions for treating for the synergistic treatment of fungal associated disorders are discussed.Type: ApplicationFiled: March 14, 2002Publication date: September 4, 2003Inventors: Michael Draper, Mark L. Nelson
-
Publication number: 20030153537Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.Type: ApplicationFiled: February 16, 2000Publication date: August 14, 2003Inventor: Stuart B. Levy
-
Patent number: 6602516Abstract: The ability to incorporate iodoform, tetracycline and a combination of iodoform/tetracycline into root canal gutta percha points is described. The iodoform, tetracycline and iodoform/tetracycline combination are bound within the gutta percha points. They act as a reservoir of antimicrobial that is capable of diffusing onto the surface of the gutta percha thereby inhibiting the colonization of bacteria on the gutta percha points and within the root canal system. Tetracycline is capable of coalescing within the dentinal tubules to inhibit long term microbial growth. These medicated gutta percha points are site specific, surface acting antimicrobial gutta percha points. A method of the usage and delivery of amorphous form iodoform gutta percha, iodoform/tetracycline gutta percha, or tetracycline gutta percha within a heated compule with a pressure plunger by delivering the thermo-softened heat labile amorphous form via a pressure extrusion system through a cannula into the prepared root canal system.Type: GrantFiled: November 2, 2000Date of Patent: August 5, 2003Inventor: Howard Martin
-
Publication number: 20030096008Abstract: An antibiotic product for delivering at least Tetracycline or Doxycycline that is comprised of three dosage forms with different release profiles with each of Tetracycline and Doxycycline being present in at least one of the dosage forms.Type: ApplicationFiled: March 7, 2002Publication date: May 22, 2003Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
-
Publication number: 20030039704Abstract: The invention provides a method of treating or preventing rosacea, comprising topical administration, of a pharmaceutical preparation comprising a nonsteroidal anti-inflammatory drug (NSAID).Type: ApplicationFiled: March 15, 2002Publication date: February 27, 2003Inventors: Moshe Arkin, Marcel Zighelboim, Ilana Lavon, Amira Zeevi
-
Publication number: 20030004118Abstract: Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife and convenient dispensing and application are provided.Type: ApplicationFiled: April 12, 2002Publication date: January 2, 2003Inventors: Mohan Vishnupad, Naomi Vishnupad
-
Publication number: 20020168368Abstract: A composition including a purified antibody conjugated with at least one antibiotic, the antibody having an antigen-binding portion that binds at least one antigen derived from Staphylococcus or Streptococcus.Type: ApplicationFiled: June 27, 2002Publication date: November 14, 2002Inventor: Stanley A. Kim
-
Patent number: 6462025Abstract: Two separate compositions, one containing an antibiotic and one containing benzoyl peroxide are packaged within and dispensed from a common dispenser. More particularly, a dual dispenser contains i) a first composition that is substantially anhydrous and includes a polar solvent, an antibiotic and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides; and ii) a second composition containing benzoyl peroxide or, alternatively, a retinoid. By packaging these two anti-acne active ingredients in this manner, long shelflife and convenient dispensing and application are provided.Type: GrantFiled: December 12, 2000Date of Patent: October 8, 2002Assignee: Imaginative Research Associates, Inc.Inventor: Mohan Vishnupad
-
Publication number: 20020119950Abstract: The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, and anti-oxidant agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, and L-ergothionine and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.Type: ApplicationFiled: February 12, 1999Publication date: August 29, 2002Inventors: TODD R. DVM HENDERSON, BARBARA E.RN. DVM CORSON, TAREK HAMMAD, MEDHAT SOLIMAN, LOUIS LIPPIELLO
-
Publication number: 20020119952Abstract: This invention relates to the compositions and method of treating and preventing arthritis, repairing of articular joint surfaces and the relief of symptoms associated with arthritis. The composition comprises bio-affecting agents to reduce nitric oxide production and increase chondroprotective agents. The preferred composition comprises; nitric oxide synthase inhibitors, nitric oxide scavangers, and amino sugars. Nitric oxide synthase inhibitors and nitric oxide scavengers reduce the level of nitric oxide, the free radical responsible for the degradation of articular cartilage. Amino sugars are the building blocks of articular cartilage and have anti-inflammatory actions.Type: ApplicationFiled: February 5, 2002Publication date: August 29, 2002Inventor: Edward J. Petrus
-
Patent number: 6432935Abstract: Compositions comprising an antibiotic, sulphonamide, at least one an antiquagul agent, e.g., clotrimazol (bis-phenyl-(2-chlorophenyl)-1-imidazolyl-methane), natamycin, or nystatin,and 5-nitro-metronidazol (5-nitro-inidazoles) e.g., (metronidazol or tinidazol or nimorazol) and a pharmaceutically acceptable carrier. The compositions are useful mainly as vaginal suppositories.Type: GrantFiled: January 22, 1997Date of Patent: August 13, 2002Inventor: Márton Milánkovits
-
Publication number: 20020106339Abstract: Compositions and methods are provided for ameliorating various effects of UVA and UVB radiation from the sun. The compositions include an ingredient that prevents photoaging from MED and subMED radiation, namely a direct acting MMP (matrix metalloproteinase) inhibitor. The compositions can include another, indirect MMP inhibitor, such as a retinoid, certain other compounds (such as N-acetylcysteine, 2-furildioxime, and vitamin C), tetracyclines, and if a retinoid is used then in addition optional compounds that inhibit the CYP-26 (chytochrome P-450) mediated metabolism of retinoids such as ketoconazole and other azole compounds. In the method, the composition is applied prior to exposure to the sun; for direct acting MMP inhibitors, application should be just prior to exposure, and if indirect inhibitors such as retinoids are used in addition, then application of the indirect inhibitor should be at least about seven hours prior to exposure.Type: ApplicationFiled: April 2, 2002Publication date: August 8, 2002Inventors: Gary J. Fisher, John J. Voorhees, Sewon Kang
-
Publication number: 20020090397Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.Type: ApplicationFiled: March 13, 2002Publication date: July 11, 2002Applicant: Byk Gulden Lomberg Chemische Fabrik GmbHInventors: Rudolf Linder, Rango Dietrich
-
Publication number: 20020058616Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: April 10, 2001Publication date: May 16, 2002Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6365600Abstract: This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyul, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(=))—R9 or —Alk1—S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1Ar2C1-6alkyl, Ar2-oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6-alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbony, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkul or C1-6alkylS(O)2C1-6alkyl; R6 and R7 independenly areType: GrantFiled: November 30, 1999Date of Patent: April 2, 2002Assignee: Janssen Pharmaceutica, N.V.Inventors: David William End, Michael J. Zelesko
-
Publication number: 20020028222Abstract: The present application relates to the use of fibers in a skincare composition or a make-up composition for the skin, to make the complexion matte, smooth and/or uniform, and/or to fade out skin relief defects. The fibers are in particular polyamide fibers having a length of from 1 &mgr;m to 10 mm and a shape factor of from 5 to 150. The composition used gives the skin a covering index of greater than 0.1 and preferably greater than 0.13. The invention also relates to a cosmetic treatment process for fading the complexion matte, smooth and/or uniform, and/or for fading out microreliefs, wrinkles, fine lines and pores in the skin, comprising the application to the skin of fibers in a cosmetic composition.Type: ApplicationFiled: May 3, 2001Publication date: March 7, 2002Applicant: L'OREALInventor: Isabelle Afriat
-
Publication number: 20020001573Abstract: The present invention comprises a method for the treatment of cancerous tumors in mammals comprising the administration of an effective amount of an immunostimulator which enhances and potentiates the mammals own immune system to selectively attack and kill the cancerous cells. The immunostimulator, preferably urushiol, is administered in a pharmaceutically acceptable carrier and can be co-administered in conjunction with other immunostimulators, radiation therapy or other cytotoxic anti-cancer agents to further enhance their effect.Type: ApplicationFiled: June 11, 2001Publication date: January 3, 2002Inventor: Alain Martin
-
Publication number: 20010056085Abstract: The present invention relates to methods of treating, as well as preventing extravasation injury. In particular, the present invention pertains to photochemotherapeutic methods of prophylaxis and/or treatment of extravasation injury induced by vesicant antineoplastic drugs and other pharmaceutical formulations. In accordance with the present invention, extravasation injury is prevented or minimized by the coadministration of photoinactivation inducing compounds in a formulation comprising a vesicant antineoplastic or other pharmaceutical formulation, and subsequently exposing the injection or infusion site to photoexciting light.Type: ApplicationFiled: March 9, 2001Publication date: December 27, 2001Inventor: Avner Ramu
-
Patent number: 6326364Abstract: A method of inhibiting the growth of a bacterial species in a human or non-human vertebrate employs the antimicrobial (i.e., antibiotic) properties of 5-aminosalicylates. These antimicrobial properties are also employed in an antimicrobial method of inhibiting the growth of a bacterial species in a foodstuff and in foodstuffs containing a 5-aminosalicylate compound. Pharmaceutical compositions, foodstuffs, food containers, food-handling implements, cleansers, polishes, paints, sprays, soaps, or detergents comprise 5-aminosalicylate compounds, such as mesalamine, sulphasalazine, olsalazine, ipsalazine, salicylazobenzoic acid, balsalazide, or conjugated bile acids, including ursodeoxycholic acid-5-aminosalicylic acid. The present pharmaceutical compositions can be formulated for ingestive, colonic, or topical non-systemic delivery systems or for any systemic delivery systems. Formulation can be for human or veterinary administration.Type: GrantFiled: February 8, 1999Date of Patent: December 4, 2001Assignee: Cedars-Sinai Medical CenterInventors: Henry C. Lin, Mark Pimentel
-
Publication number: 20010041737Abstract: The presence of a small amount of an antibiotic, such as metronidazole or a salt or derivative thereof, in warfarin-containing rodent baits enhances the toxicity of warfarin against rodents which have heretofore shown apparent resistance to warfarin.Type: ApplicationFiled: June 18, 2001Publication date: November 15, 2001Applicant: Reckitt Benckiser Inc., Delaware corporationInventor: Richard M. Poche
-
Patent number: 6277829Abstract: The present invention describes a process for the preparation of aqueous formulations containing azithromycin for ophthalmic use, as well any formulations obtained by this process and their topical use in the ocular bacterial infections, more preferably in the treatment of conjunctivitis, keratitis and blepharitis.Type: GrantFiled: December 27, 1999Date of Patent: August 21, 2001Assignee: S.I.F.I. Societa Industria Farmaceutica Italiana S.p.A.Inventors: Antonino Asero, Maria Grazia Mazzone, Valeria Moschetti, Anna Rita Blanco
-
Publication number: 20010011097Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosedType: ApplicationFiled: March 7, 2001Publication date: August 2, 2001Inventors: Stephen T. Sonis, Edward G. Fey
-
Patent number: 6248730Abstract: The presence of a small amount of an antibiotic, such as tetracycline or a salt or derivative thereof, in warfarin-containing rodent baits enhances the toxicity of warfarin against rodents which have heretofore shown apparent resistance to warfarin.Type: GrantFiled: February 3, 1999Date of Patent: June 19, 2001Assignee: Reckittt Benckiser Inc.Inventor: Richard M. Poché
-
Patent number: 6114316Abstract: Tissue-destructive conditions related to excess protemase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.Type: GrantFiled: September 2, 1999Date of Patent: September 5, 2000Assignee: Research Foundation of S.U.N.Y.Inventors: Nungavarm S. Ramamurthy, Lorne M. Golub, Timo A. Sorsa, Olli P. Teronen, Tuula A. Salo